8-K: Mirum Acquires Bluejay, Expands Rare Liver Disease Pipeline

Mirum Pharmaceuticals announced the acquisition of Bluejay Therapeutics for $620 million upfront plus milestones, significantly expanding its rare liver disease portfolio with late-stage asset brelovitug and securing $200 million in private placement funding.

Summary

• Mirum Pharmaceuticals, Inc. (Mirum) entered into an Agreement and Plan of Merger and Reorganization to acquire Bluejay Therapeutics, Inc. (Bluejay) on December 6, 2025.
• The acquisition involves an upfront payment of $250 million in cash and up to 5,196,009 shares of Mirum common stock, valued at approximately $370 million based on a volume-weighted average closing price of $71.2085 per share.
• Additional milestone payments of up to $200 million in cash are contingent upon the achievement of certain net sales milestones for acquired products.
• The acquisition will grant Mirum worldwide rights to brelovitug, an investigational, highly potent, pan-genotypic, fully human immunoglobulin G1 monoclonal antibody targeting chronic hepatitis D virus (HDV) and chronic hepatitis B virus (HBV).
• Brelovitug has received Breakthrough Therapy designation from the U.S. FDA, PRIME scheme designation from the European Medicines Agency (EMA), and Orphan Medicinal Product designation by the European Commission for HDV.
• Bluejay's in-licensed composition of matter patent for brelovitug expires in July 2041, subject to potential patent term extension.
• HDV is the most severe form of viral hepatitis, affecting approximately 40,000 people in the United States and over 230,000 in the US and Europe, with an estimated worldwide total annual revenue potential for brelovitug in HDV exceeding $750 million.
• Brelovitug demonstrated strong antiviral activity in Phase 2 studies for HDV, achieving 100% HDV ribonucleic acid response along with improvements in alanine aminotransferase enzyme levels and a favorable safety profile.
• The acquisition is expected to close in the first quarter of 2026, subject to regulatory approval and customary closing conditions.
• Concurrently, Mirum entered into a Subscription Agreement on December 7, 2025, with PIPE Investors to purchase 2,385,149 shares of common stock and 536,412 pre-funded warrants for an aggregate gross purchase price of approximately $200 million.
• The purchase price per PIPE Share is $68.48 (or $68.4799 per Pre-Funded Warrant, less $0.0001 exercise price).
• Mirum anticipates receipt of top-line data from the VISTAS Phase 2b clinical trial of volixibat for primary sclerosing cholangitis (PSC) in the second quarter of 2026.
• A New Drug Application (NDA) submission to the FDA for volixibat for PSC is expected in the second half of 2026, with potential approval and launch in the first half of 2027.
• Mirum expects to be cash flow positive in 2025 with anticipated full year 2025 net product sales guidance of $500-510 million.

Sentiment

Score: 8

Explanation: The acquisition of a late-stage asset with strong clinical data and regulatory designations in a high-unmet-need market, coupled with successful financing, represents a significant positive strategic move for Mirum. While integration and development risks exist, the overall outlook is highly favorable for growth and market expansion.

Positives

• Strategic acquisition of a late-stage asset, brelovitug, significantly expands Mirum's rare liver disease portfolio and global leadership.
• Brelovitug addresses a high unmet medical need in chronic hepatitis D virus (HDV), a severe viral hepatitis with no FDA-approved treatments and a worldwide total annual revenue potential of over $750 million.
• Brelovitug has received FDA Breakthrough Therapy designation and EMA PRIME and Orphan designations, indicating strong regulatory support and potential for expedited review.
• Phase 2 data for brelovitug showed strong antiviral activity, including 100% HDV RNA response and a favorable safety profile.
• The acquisition adds a fourth potential registrational readout for Mirum within the next 18 months, diversifying and strengthening its clinical pipeline.
• The concurrent private placement of approximately $200 million in gross proceeds provides funding for clinical development and commercial activities post-acquisition.
• Mirum expects to be cash flow positive in 2025, with strong net product sales guidance of $500-510 million, indicating a solid financial foundation for expansion.

Negatives

• The acquisition involves significant upfront cash and stock consideration, potentially leading to shareholder dilution from the issuance of 5,196,009 shares for the acquisition and an additional 2,385,149 shares plus 536,412 pre-funded warrants in the private placement.
• A portion of the acquisition consideration (up to $200 million) is tied to sales-based milestones, introducing future performance-based payment obligations.
• The success of brelovitug is dependent on positive Phase 3 clinical trial results and subsequent regulatory approvals, which are inherently uncertain.

Risks

• Risks and uncertainties inherent with the acquisition of companies, including potential delays or failure to receive regulatory approval and satisfy closing conditions.
• Risks and uncertainties inherent with private placements, including the successful and timely completion of the private placement.
• Risks associated with the development of acquired product candidates, including the failure of any expected synergies to be realized.
• Risks and uncertainties arising from the integration of an acquired company, its employees, and its assets with Mirum's business.
• Risks associated with evaluating companies and assets for acquisition, including that the perceived benefits of the acquisition are not realized.
• Risks and uncertainties with the development of investigational medicines generally, including the failure of future studies to generate the same or similar data as prior studies.
• Potential that estimated patient populations and disease prevalences are materially inaccurate.
• Litigation relating to the transactions discussed in the filing.
• Risks that the mergers disrupt the current plans or operations of Mirum.
• The ability of Mirum to retain and hire key personnel.
• Unexpected costs, charges, or expenses resulting from the mergers.
• Potential adverse reactions or changes to relationships with customers, suppliers, distributors, and other business partners resulting from the announcement or completion of the mergers.
• Impact of geopolitical and macroeconomic events on Mirum's business.

Future Outlook

Mirum anticipates a strong future outlook, with the acquisition of brelovitug adding a significant late-stage asset to its pipeline. The company expects multiple registrational top-line data readouts in the next 18 months, including for brelovitug in HDV (interim Q2 2026, top-line 2H 2026) and volixibat in PSC (top-line Q2 2026). Potential BLA submissions and launches for brelovitug in HDV and volixibat in PSC are projected for 2027. Further data from Livmarli EXPAND, volixibat PBC, and MRM-3379 are expected in 2027. Mirum also projects to be cash flow positive in 2025 with strong net product sales.

Management Comments

• Chris Peetz, CEO of Mirum Pharmaceuticals, stated, 'This acquisition fits squarely with what we do best advancing high-impact medicines for patients with rare diseases through disciplined development, regulatory innovation, and commercial excellence.'
• Peetz also noted, 'Brelovitug in HDV leverages our deep expertise in rare liver disease and builds on the relationships we've established with key providers through the volixibat and LIVMARLI programs.'
• Keting Chu, Founder and CEO of Bluejay Therapeutics, commented, 'Brelovitug has the potential to redefine HDV treatment, and Mirum's rare disease leadership, commitment to rare liver communities and commercialization expertise make it the right company to carry this program forward globally.'

Industry Context

The acquisition positions Mirum Pharmaceuticals as a stronger leader in the rare liver disease space, particularly by targeting chronic hepatitis D virus (HDV). HDV is highlighted as the most severe form of viral hepatitis, affecting a significant global population (over 12 million worldwide) with a high unmet medical need, as there are currently no FDA-approved treatments. The rapid progression of HDV to liver cirrhosis, liver cancer, and liver-related death underscores the urgency for new therapies. Brelovitug's pan-genotypic nature and Breakthrough Therapy designation suggest it could be a significant advancement in this underserved market, aligning with broader industry trends focusing on orphan diseases and high-impact medicines.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the acquisition against global benchmarks. However, the lack of approved treatments for HDV in the U.S. and most countries worldwide positions brelovitug as a potential first-in-class therapy, which is a significant competitive advantage.
• Brelovitug's FDA Breakthrough Therapy and EMA PRIME designations indicate that regulatory bodies recognize its potential to offer a substantial improvement over existing therapies for a serious condition, suggesting a high standard of clinical promise.

Stakeholder Impact

• **Shareholders:** Potential for significant long-term value creation through pipeline expansion and entry into a high-value market, but also immediate dilution from stock issuance for the acquisition and private placement.
• **HDV Patients:** Significant positive impact as brelovitug offers a potential new treatment option for a severe disease with no currently approved therapies.
• **Employees:** Bluejay employees will be integrated into Mirum, potentially leading to new opportunities and roles. Mirum employees may see expanded responsibilities and a strengthened company outlook.
• **Customers/Healthcare Providers:** Expanded product offerings in rare liver diseases, leveraging Mirum's existing relationships and expertise.
• **Bluejay Security Holders:** Receive substantial upfront cash and Mirum common stock, plus potential future milestone payments, providing a clear exit and potential upside.

Next Steps

• Closing of the Mergers in the first quarter of 2026, subject to regulatory approval and customary closing conditions.
• Interim analysis of the AZURE 1 Phase 3 study for brelovitug in HDV in Q2 2026.
• Receipt of top-line data from the VISTAS Phase 2b clinical trial of volixibat for PSC in Q2 2026.
• Receipt of top-line data from AZURE 1 and AZURE 4 Phase 3 studies for brelovitug in HDV in 2H 2026.
• Submission of a New Drug Application (NDA) to the FDA for volixibat for PSC in 2H 2026.
• Potential Biologics License Application (BLA) submission to the FDA for brelovitug in HDV in 1H 2027.
• Potential approval and launch of volixibat for PSC in 1H 2027, if approved.
• Potential approval and launch of brelovitug in HDV in 2H 2027, if approved.
• Receipt of top-line data from the Phase 3 Livmarli EXPAND clinical trial, the Phase 2b volixibat clinical trial for PBC, and the Phase 2 clinical trial of MRM-3379 for Fragile-X Syndrome in 2027.
• Evaluation of strategic options for Bluejay's additional investigational programs after the close of the acquisition.

Key Dates

Recommendation

The acquisition of Bluejay Therapeutics is a highly strategic move for Mirum, significantly enhancing its late-stage pipeline with brelovitug, a promising asset for chronic HDV, a disease with a substantial unmet medical need and no approved treatments. Brelovitug's strong Phase 2 data and multiple expedited regulatory designations (FDA Breakthrough, EMA PRIME) de-risk its development and indicate a high probability of market entry and commercial success. The concurrent $200 million private placement demonstrates strong investor confidence and provides ample funding for the expanded pipeline, mitigating immediate financial concerns. This transaction leverages Mirum's existing expertise in rare liver diseases and its established commercial infrastructure, creating strong synergies. The potential for multiple registrational readouts in the near term further strengthens the company's growth profile, making it an attractive investment for long-term growth in the rare disease sector.

Keywords

Mirum Pharmaceuticals, Bluejay Therapeutics, Acquisition, Merger, Brelovitug, Hepatitis Delta Virus, HDV, Rare Liver Disease, Biotechnology, Pharmaceuticals, Clinical Trials, Phase 3, Breakthrough Therapy, PRIME Designation, Private Placement, Capital Raise, Volixibat, Primary Sclerosing Cholangitis, PSC, Pipeline Expansion, MIRM, SEC Filing, 8-K